Molecular structure of RAD51 Inhibitor B02, CAS Number: 1290541-46-6
RAD51 Inhibitor B02 (CAS 1290541-46-6)
CAS Number:
1290541-46-6
Molecular Weight:
339.4
Molecular Formula:
C22H17N3O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
RAD51 Inhibitor B02 (CAS 1290541-46-6) References
- Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival. | Herrero, AB. and Gutiérrez, NC. 2017. Front Oncol. 7: 98. PMID: 28580318
- Synergistic Antiproliferative Activity of the RAD51 Inhibitor IBR2 with Inhibitors of Receptor Tyrosine Kinases and Microtubule Protein. | Ferguson, PJ., et al. 2018. J Pharmacol Exp Ther. 364: 46-54. PMID: 29061656
- Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models. | Sambade, MJ., et al. 2019. Neurooncol Adv. 1: vdz005. PMID: 32642648
- DNA-protein crosslinks are repaired via homologous recombination in mammalian mitochondria. | Chesner, LN., et al. 2021. DNA Repair (Amst). 97: 103026. PMID: 33316746
- Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress. | Lindemann, A., et al. 2021. Mol Cancer Ther. 20: 1257-1269. PMID: 33947685
- Inhibition of the DSB repair protein RAD51 potentiates the cytotoxic efficacy of doxorubicin via promoting apoptosis-related death pathways. | Schürmann, L., et al. 2021. Cancer Lett. 520: 361-373. PMID: 34389435
- EGFR-mediated Rad51 expression potentiates intrinsic resistance in prostate cancer via EMT and DNA repair pathways. | Rajput, M., et al. 2021. Life Sci. 286: 120031. PMID: 34627777
- Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma. | Samadaei, M., et al. 2022. J Cell Biochem. 123: 1663-1673. PMID: 36271841
- Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer. | Li, M., et al. 2022. Oncogene. 41: 5331-5346. PMID: 36344674
- RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma. | Tsai, YF., et al. 2023. Cancer Cell Int. 23: 231. PMID: 37798649
Inhibitor of:
2610002J02Rik, 53BP1, APLF, BRCAA1, C17orf53, DNA Ligase IV, DNA pol θ, ESCO2, Factor VII, GBDR1, Hop2, Hus1, MEI1, MEIOB, PIERCE 1, PNK, Rad1, Rad26, Rad51, RAD51AP1, Rad51C, Rad52, RAD54L2, Rad57, Rad59, RAP80, RECA-1, REV1, RMI2, RNase HII-A, SLX1A/B_SLX1, SMC6, Spo11, translin, XRCC3, and XRCC4.Activator of:
CENP-H, F730047E07Rik, FIGNL1, Hfm1, MND1, Morc2b, RAD51AP2, TIPIN, and ZSWIM7.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
RAD51 Inhibitor B02, 10 mg | sc-507533 | 10 mg | $95.00 |